Keybank National Association OH Decreases Stake in Zoetis Inc. (NYSE:ZTS)

Keybank National Association OH decreased its holdings in Zoetis Inc. (NYSE:ZTS) by 4.4% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 233,235 shares of the company’s stock after selling 10,613 shares during the period. Keybank National Association OH owned approximately 0.05% of Zoetis worth $38,001,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Darwin Wealth Management LLC purchased a new position in shares of Zoetis in the 3rd quarter valued at $31,000. First Personal Financial Services purchased a new position in Zoetis in the third quarter valued at about $33,000. Capital Performance Advisors LLP purchased a new position in Zoetis in the third quarter valued at about $33,000. Dunhill Financial LLC lifted its stake in shares of Zoetis by 80.6% during the third quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock worth $33,000 after purchasing an additional 75 shares in the last quarter. Finally, Atlantic Edge Private Wealth Management LLC boosted its position in shares of Zoetis by 482.8% in the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock worth $28,000 after buying an additional 140 shares during the period. 92.80% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the firm’s stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total value of $55,804.68. Following the sale, the executive vice president now owns 16,107 shares in the company, valued at approximately $2,757,196.26. This trade represents a 1.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.16% of the stock is currently owned by insiders.

Analysts Set New Price Targets

ZTS has been the topic of several analyst reports. UBS Group assumed coverage on Zoetis in a report on Monday, December 9th. They set a “neutral” rating and a $196.00 target price on the stock. StockNews.com lowered shares of Zoetis from a “buy” rating to a “hold” rating in a research note on Tuesday, February 25th. Barclays upped their target price on shares of Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a research note on Friday, February 14th. Stifel Nicolaus dropped their price target on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. Finally, Morgan Stanley reduced their price target on Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a report on Friday, February 14th. Two equities research analysts have rated the stock with a hold rating, nine have given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Zoetis has a consensus rating of “Buy” and an average price target of $215.90.

Zoetis Stock Performance

ZTS stock opened at $169.79 on Wednesday. The stock’s 50 day simple moving average is $166.53 and its 200 day simple moving average is $177.06. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $200.33. The firm has a market cap of $76.03 billion, a P/E ratio of 31.04, a P/E/G ratio of 2.78 and a beta of 0.90.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.37 by $0.03. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The business had revenue of $2.32 billion for the quarter, compared to the consensus estimate of $2.30 billion. As a group, equities research analysts predict that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be issued a $0.50 dividend. The ex-dividend date is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.18%. Zoetis’s dividend payout ratio (DPR) is presently 36.56%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.